Skyrizi Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

NORTH CHICAGO, Ill., June 15, 2023. AbbVie today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint of clinical remission...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials